African-American women with type 2 diabetes may have higher risk for ER-neg breast cancer

November 15, 2017

Bottom Line: Among African-American women, those with type 2 diabetes may have a higher risk of developing estrogen receptor (ER)-negative breast cancer.

Journal in Which the Study was Published: Cancer Research, a journal of the American Association for Cancer Research

Author: Julie R. Palmer, ScD, associate director of Boston University's Slone Epidemiology Center, professor of epidemiology at Boston University School of Public Health, and associate director for population sciences at the BU-BMC Cancer Center

Background: The majority of breast cancers are ER-positive; this type of breast cancer is the easiest to treat and has the highest survival rate. African-American women are disproportionally affected by ER-negative breast cancers, with double the incidence as compared to white women, said Palmer.

"We are still trying to understand the basic biological processes that lead to ER-negative breast cancer. One way to do this is to study factors that are more common in an African-American population," added Palmer.

Several studies suggest that diabetes is a risk factor for breast cancer, and type 2 diabetes is twice as prevalent in African-American women as compared to white women, commented Palmer. One previous study analyzed the association with type 2 diabetes and breast cancer in African- American women, but did not report results separately for ER-negative and ER-positive breast cancer. How the Study Was Conducted: The analyses conducted by Palmer and colleagues were based on information provided by participants in the Black Women's Health Study (BWHS). The BWHS was established over 20 years ago and utilizes biennial questionnaires to obtain information from 59,000 African- American women from across the United States. Using this large data set, Palmer and colleagues could control for many factors, including age and body mass index (BMI).

Results: "Our results showed statistically significant evidence of an increased risk of ER-negative breast cancer in black women who had type 2 diabetes before they ever had breast cancer, primarily in the women who had diabetes for at least five years,"said Palmer. They did not find an association with ER-positive breast cancer in the same cohort. Importantly, the association between type 2 diabetes and ER-negative breast cancer was observed only among women with lower BMI (<30). This suggests that abnormal metabolic status may play a larger role in ER-negative breast cancer than obesity, Palmer said.

Author's Comments: "Our findings may account for some of the racial disparity in breast cancer, and could partly explain why mortality from breast cancer is so much higher in black women than white women," said Palmer. She stressed that further work is needed to corroborate these relatively new findings. "If these results are confirmed, type 2 diabetes would be a modifiable risk factor for ER-negative breast cancer," noted Palmer. "Women could reduce their chances of getting ER-negative breast cancer if they could avoid developing type 2 diabetes. Monitoring of blood sugar levels to identify pre-diabetes may allow for early interventions to prevent diabetes." Palmer's future work includes testing if diabetes medication, such as metformin, could lower the risk for ER-negative breast cancer.

Study Limitations: Limitations of the study include a dependence on self-reports rather than medical records for classification of type 2 diabetes status. Additionally, due to the relatively small sample size in specific subgroups, there was a lack of statistical power for the analysis of medication use.
-end-
Funding & Disclosures: This study was funded by the National Institutes of Health and in part by the Dahod Breast Cancer Research Program at the Boston University School of Medicine. Palmer declares no potential conflicts of interest.

To interview Julie Palmer, contact Julia Gunther at julia.gunther@aacr.org or 215-446-6896.

Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 21,900 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.

American Association for Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.